Early detection of amyloidosis in monoclonal gammopathy
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Hormones & metabolism, Immune system & allergy clinical trials.
This study uses special imaging to look for early signs of amyloidosis in people who have a condition called monoclonal gammopathy. Finding amyloidosis early can help doctors manage it better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be part of the COSMO-AL study.
- You need to have had a biopsy test done.
- You must give your written permission to join.
- You cannot be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is for people who are newly diagnosed with either a very early blood condition (MGUS or smoldering myeloma) or AL amyloidosis, and who have not yet had treatment. It aims to help doctors better diagnose and manage these conditions in Italy.
This research study looks at how certain sugar molecules (N-glycosylation) on proteins may play a role in a disease called AL amyloidosis. Researchers will study blood samples from people with related plasma cell disorders to learn more about these sugars, which could help with diagnosis and treatment.
This study tests a medicine called anselamimab for people with a rare, localized form of amyloidosis (a buildup of abnormal protein) that forms a lump and has not spread to major organs. The goal is to see if the medicine can shrink or remove these deposits safely.
This study collects blood and other samples, along with health information, from people who have—or might have—amyloidosis. It aims to improve understanding of the disease and support future treatments.
This trial tests a combination of three drugs—bortezomib, pomalidomide, and dexamethasone—to see how well they work for people with AL amyloidosis, a condition where abnormal proteins build up in organs. You may join if you are newly diagnosed or have had prior treatment and your organs are affected.
This study follows people with early, “precursor” blood conditions to learn what changes in their blood or bone marrow signal progression. It may help doctors better predict outcomes and understand why some people develop symptom-causing cancer.
Hear when a new Monoclonal Gammopathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.